A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
Completed
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/02/2022
Locations: National Research Institute, Huntington Park, California +79 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets
NCT05606471
Unknown
The very-low calorie diet (VLCD) is a highly effective and safe way to rapidly lose significant amounts of weight and dramatically improve blood sugar control in a short period of time (typically 8-12 weeks). It has recently become recommended by the UK National Health Service as a treatment for selected patients with type 2 diabetes. One drawback of VLCD however is the associated loss of skeletal muscle which affects some patients. Semaglutide is a well-known medication for type 2 diabetes tha... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/31/2022
Locations: University of Nottingham, Royal Derby Hospital Centre, Derby, Not set
Conditions: Type 2 Diabetes Mellitus in Obese
Register for Updates
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
NCT02607865
Completed
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +241 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT02692716
Completed
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Little Rock, Arkansas +228 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
NCT04615871
Unknown
With the results of this study the investigators aim to identify an effective treatment that will reduce morbidity and mortality of patients with symptomatic COVID-19 infection, which would in turn reduce the burden on the healthcare system by decreasing the need for intensive care. Objectives: The main objective of this research is to determine if once weekly treatment with the GLP-1 agonist semaglutide for 4 doses will reduce cardiac as well as non-cardiac complications of COVID-19 infection.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2022
Locations: Instituto Prevent Senior, São Paulo, Not set +9 locations
Conditions: Covid19, Myocardial Injury
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Cahaba Research, Birmingham, Alabama +126 locations
Conditions: Type 2 Diabetes
Register for Updates
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548935
Completed
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which tre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +127 locations
Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity
Register for Updates
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
NCT02970942
Completed
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/15/2021
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +157 locations
Conditions: Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
Register for Updates
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
NCT03552757
Completed
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2021
Locations: Novo Nordisk Investigational Site, Buena Park, California +146 locations
Conditions: Obesity, Overweight
Register for Updates
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)
NCT03876015
Completed
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2021
Locations: Novo Nordisk Investigational Site, Atherstone, Not set +30 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT01923181
Completed
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2021
Locations: Novo Nordisk Investigational Site, Tucson, Arizona +102 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
NCT02773381
Completed
This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric emptying in subjects with Type 2 diabetes
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/04/2020
Locations: Novo Nordisk Investigational Site, Leeds, Not set
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates